Twist Bioscience Collaborates with Adicet Bio to Accelerate Discovery of Gamma Delta T Cell Cancer Therapeutics
September 13 2021 - 8:00AM
Business Wire
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, and Adicet Bio, Inc. (Nasdaq:
ACET), a biotechnology company discovering and developing
first-in-class allogeneic gamma delta T cell therapies for cancer
and other diseases, today announced a collaboration to accelerate
the discovery of gamma delta T cell therapies against five
undisclosed targets. The companies will work together to engineer
immune cells with fully human chimeric antigen receptors (CARs) and
T-cell receptors (TCRs) directed to disease-specific cell surface
antigens. This precise and targeted engagement is designed to
provide a superior potential to facilitate recognition and killing
of tumor cells.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210913005263/en/
Under the terms of the collaboration, Twist will leverage its
proprietary single chain fragment variable (scFv) and VHH
(nanobody) technologies from its Library of Libraries to discover
unique target-specific binders. These targeting technologies will
enable Adicet Bio’s engineering and discovery of unique CARs used
in the generation of novel gamma delta CAR T cell products. Twist
will receive an upfront technology license fee for each program as
well as clinical and regulatory milestones and royalties for any
product resulting from the selected targets.
“We are excited to leverage Twist’s proprietary antibody
discovery capabilities to potentially rapidly identify and optimize
unique antibodies against key targets to further enhance our
pipeline, both in cancer and other diseases,” said Chen Schor,
President and Chief Executive Officer of Adicet. “We’ve selected
five key targets where we believe our expertise in gamma delta T
cell therapies could be augmented with Twist’s ability to identify
highly potent, specific antibodies and look forward to a robust
partnership.”
“There is huge potential in using gamma delta T cells for the
treatment of a wide range of cancers, and Adicet is leading the
development in this field,” commented Emily M. Leproust, Ph.D., CEO
and co-founder of Twist Bioscience. “We look forward to partnering
with Adicet to translate these target-engagement technologies into
next-generation off-the-shelf, CAR-T therapies and to potentially
accelerate the treatment of patients with cancer.”
About Adicet Bio
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in patients.
For more information, please visit our website at
http://www.adicetbio.com.
Forward-Looking Statements – Adicet Bio
This press release contains "forward-looking statements" of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet
including, but not limited to, express or implied statements
regarding the potential benefits resulting from the collaboration
with Twist to our business or strategy, including our ability to
rapidly identify and optimize unique antibodies and related
target-engagement technologies to facilitate our CAR pipeline, the
payment of upfront license fees and potential milestone and royalty
payments under the collaboration, the expected potential
therapeutic effects of Adicet’s product candidates, and
expectations regarding the timing and success of preclinical and
clinical development of Adicet’s product candidates, including in
connection with the collaboration. Any forward-looking statements
in this press release are based on management’s current
expectations and beliefs of future events, and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially and adversely from those set forth in or
implied by such forward-looking statements, including without
limitation, the effect of COVID-19 on Adicet’s business and
financial results, including with respect to disruptions to its
clinical trials and business operations; future clinical studies
may fail to demonstrate adequate safety and efficacy of our product
candidates, which would prevent, delay, or limit the scope of
regulatory approval and commercialization; regulatory approval
processes of the FDA and comparable foreign regulatory authorities
are lengthy, time-consuming, and inherently unpredictable; as well
as those risks and uncertainties set forth in Adicet’s most recent
annual report on Form 10-K and subsequent filings with the
Securities and Exchange Commission (SEC). For a discussion of these
and other risks and uncertainties, and other important factors, any
of which could cause Adicet’s actual results to differ from those
contained in the forward-looking statements, see the section
entitled “Risk Factors” in Adicet’s most recent annual report on
Form 10-K and periodic reports on Form 10-Q and Form 8-K filed with
the SEC, as well as discussions of potential risks, uncertainties,
and other important factors in Adicet’s other filings with the SEC.
All information in this press release is as of the date of the
release, and Adicet undertakes no duty to update this information
unless required by law.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including but not limited to the ability of the
collaboration to accelerate the discovery of gamma delta T cell
therapies, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021 and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210913005263/en/
For Twist Bioscience Angela Bitting SVP, Corporate
Affairs 925- 202-6211 media@twistbioscience.com
For Adicet Bio, Inc.: Anne Bowdidge
abowdidge@adicetbio.com Janhavi Mohite Stern Investor Relations,
Inc. 212-362-1200
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Apr 2023 to Apr 2024